The spinal muscular atrophy (SMA) treatment ‘Evrysdi (risdiplam)’ finally passed the final hurdle to its reimbursement in Korea

According to industry sources, both SMA treatments, Biogen Korea’s ‘Spinraza (nusinersen)’ and Roche Korea’s treatment ‘Evrysdi (risdiplam),’ reached a final agreement with the National Health Insurance Service after drug pricing negotiation. The discussions were being made for Spinraza's reimbursement extension and the new listing of Evrysdi.

As a result, the two drugs are expected to be listed for reimbursement starting next month (October) if no unexpected events arise.

The current reimbursement standard for Spinraza is 5q which satisfi